Working... Menu

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01849874
Recruitment Status : Active, not recruiting
First Posted : May 9, 2013
Last Update Posted : January 11, 2019
Information provided by (Responsible Party):
Array BioPharma

Brief Summary:
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Patients may be eligible to crossover from physician's choice chemotherapy to MEK162 if they meet certain inclusion criteria including centrally confirmed disease progression. Approximately 360 patients from North America, Europe and Australia will be enrolled in this study.

Condition or disease Intervention/treatment Phase
Low-grade Serous Ovarian Cancer Low-grade Serous Fallopian Tube Cancer Low-grade Serous Peritoneal Cancer Drug: MEK162, MEK inhibitor; oral Drug: Physician's choice chemotherapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : June 2013
Actual Primary Completion Date : April 1, 2016
Estimated Study Completion Date : September 2019

Arm Intervention/treatment
Experimental: MEK162 Drug: MEK162, MEK inhibitor; oral
multiple dose, single schedule

Active Comparator: Physician's choice chemotherapy Drug: Physician's choice chemotherapy

Patients will receive one of the following chemotherapies as determined by the physician:

  • Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
  • Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
  • Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)

Primary Outcome Measures :
  1. Demonstrate superior efficacy of study drug vs. physician's choice of selected chemotherapies in terms of increased progression-free survival. [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Obtain additional estimates of the efficacy of study drug vs. physician's choice of selected chemotherapies in terms of overall survival, objective response rate, duration of response and disease control rate. [ Time Frame: 6 years ]
  2. Characterize the safety profile of the study drug vs. physician's choice of selected chemotherapies in terms of adverse events and clinical laboratory tests. [ Time Frame: 3 years ]
  3. Assess the effect on global health status of study drug vs. physician's choice of selected chemotherapies in terms of quality-of-life questionnaires. [ Time Frame: 3 years ]
  4. Characterize the plasma pharmacokinetics (PK) of study drug in terms of plasma concentration-time profiles and model-based PK parameters. [ Time Frame: 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma), confirmed histologically and verified by central pathology review.
  • Recurrent or persistent measurable disease that has progressed (defined as radiological and/or clinical progression; an increase in cancer antigen [CA]-125 alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal therapy, surgery) and is not amenable to potentially curative intent surgery, as determined by the patient's treating physician.
  • Must have received at least 1 prior platinum-based chemotherapy regimen but have received no more than 3 lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.
  • Available archival tumor sample (excisional or core biopsy) for confirmation of LGS carcinoma diagnosis. If adequate archival tumor sample is not available, willingness to consent to tissue biopsy.
  • Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  • Additional criteria exist.

Key Exclusion Criteria:

  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
  • Prior therapy with a MEK or BRAF inhibitor.
  • History of Gilbert's syndrome.
  • Impaired cardiovascular function or clinically significant cardiovascular diseases.
  • Uncontrolled or symptomatic brain metastases that are not stable or require steroids, are potentially life-threatening or have required radiation within 28 days prior to first dose of study treatment.
  • Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of first dose of study treatment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.
  • Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
  • Prior randomization into this clinical study.
  • Additional criteria exist.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01849874

  Hide Study Locations
Layout table for location information
United States, Arizona
Phoenix, Arizona, United States
Scottsdale, Arizona, United States
United States, California
Irvine, California, United States
Los Angeles, California, United States
United States, Colorado
Aurora, Colorado, United States
United States, Connecticut
New Haven, Connecticut, United States
United States, Florida
Orlando, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
United States, Georgia
Georgia Regents University
Augusta, Georgia, United States, 30912
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Iowa
Iowa City, Iowa, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
Grand Rapids, Michigan, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, Montana
Billings, Montana, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Bronx, New York, United States
New York, New York, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
United States, Virginia
Charlottesville, Virginia, United States
Royal Adelaide Hospital
Adelaide, Australia
Western Health
Footscray, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Mater Adult Hospital
South Brisbane, Australia
Sydney Adventist Hospital
Sydney, Australia
Burnside War Memorial Hospital
Toorak Gardens, Australia
Westmead Hospital
Westmead, Australia
University Clinic Innsbruck
Innsbruck, Austria
AKH Vienna
Vienna, Austria
Cliniques Universitaires Saint-Luc
Bruxelles, Belgium
Antwerp University Hospital
Edegem, Belgium
University Hospital Gent
Gent, Belgium
University Hospital Leuven
Leuven, Belgium
Centre Hospitalier de l' Ardenne
Libramont, Belgium
CHC Saint-Joseph
Liege, Belgium
CHR Citadelle
Liege, Belgium
Clinique Ste-Elisabeth
Namur, Belgium
Wilrijk, Belgium
Canada, Alberta
Calgary, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Winnipeg, Manitoba, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
CHUS - Hopital Fleurimont
Sherbrooke, Quebec, Canada
Masaryk Mamorial Cancer Institute
Brno, Czechia
Teaching Hospital Hradec Kralove
Hradec Kralove, Czechia
University Hospital
Olomouc, Czechia
Fakulni Nemocnice Ostrava
Ostrava-Poruba, Czechia
General University Hospital
Prague, Czechia
Hospital Na Bulovce, Institute of Radiation Oncology
Prague, Czechia
University Hospital
Aalborg, Denmark
Copenhagen, Denmark
Department of Oncology
Harlev, Denmark
Tampere University Hospital
Tampere, Finland
Institut de Cancerologie de I'ouest Paul Papin
Angers, France
CHU Jean Minjoz
Besancon, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Montpellier, France
Centre Catherine de Sienne
Nantes, France
Hopital Europeen Georges Pompidou, rue Leblanc
Paris, France
Hopital Tenon
Paris, France
Clinique Armoricaine de Radiologie
Saint-Brieuc, France
ICO Gauducheau
Saint-Herblain, France
Hopitaux Universitaires de Strasbourg
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
University Medical Center Aachen
Aachen, Germany
Charite Campus Virchow Klinikum - Frauenklinik
Berlin, Germany
University of Bonn - Department of Obstetrics and Gynecology
Bonn, Germany
Universitatsklinikum Carl Gustav Carus
Dresden, Germany
Frauenklinik University Hospital Erlangen
Erlangen, Germany
Kliniken Essen-Mitte, Evang. Huyssens Stiftung
Essen, Germany
University Hospital
Essen, Germany
University Hospital of Frankfurt
Frankfurt, Germany
University Clinic
Freiburg, Germany
Universitatsmedizin Gottingen
Gottingen, Germany
Uni-Medizin Greifswald
Greifswald, Germany
Medizinische Hochschule Hannover
Hannover, Germany
NCT - Gynecological Oncology Section - University Hospital
Heidelberg, Germany
Jena University Hospital - Department of Gynecology and Obstetrics
Jena, Germany
Klinikum Kassel
Kassel, Germany
Studienzentrale Gynakologische Onkologie
Kiel, Germany
UniversitatsKlinikum Schleswlg-Holstein
Lubeck, Germany
University Hospital of Giessen and Marburg
Marburg, Germany
Technical University Munich
Munich, Germany
Tubingen, Germany
University Hopsital of Ulm
Ulm, Germany
Hungarian Defense Forces Medical Centre
Budapest, Hungary
National Institute of Oncology
Budapest, Hungary
Semmelweis University
Budapest, Hungary
Aladar Petz County Teaching Hospital
Gyor, Hungary
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato
Miskolc, Hungary
Josa Andras Oktatokorhaz
Nyiregyhaza, Hungary
St James University Hospital
Dublin, Ireland
Centro Riferimento Oncologico
Aviano, Italy
Azienda Ospedaliero-Universitaria Policlinico Consorziale
Bari, Italy
University Hospital Consortorium Policlinico di Bari
Bari, Italy
AOU Bologna
Bologna, Italy
Divisione di Ostetricia e Ginecologia
Brescia, Italy
Azienda Ospedaliera Cannizzaro
Catania, Italy
Hospital of Faenza
Faenza, Italy
Unita Operativa di Oncologia
Faenza, Italy
Instituto Europeo Oncologico
Milano, Italy
National Cancer Institute Milan
Milan, Italy
Ospedale Niguarda Ca' Granda
Milan, Italy
A.O.U. Federico II
Naples, Italy
Istituto Nazionale Tumori di Napoli
Naples, Italy
Clinica Ostetrica e Ginecologica, Universita di Pisa
Pisa, Italy
Agostino Gemelli Teaching Hospital
Roma, Italy
Policlinico Umberto I, Sapienza
Roma, Italy
Regina Elena
Roma, Italy
Centre Hospitalier Emile Mayrisch
Esch-sur-Alzette, Luxembourg
Amsterdam, Netherlands
University Medical Center
Groningen, Netherlands
Maastricht University Medical Center+
Maastricht, Netherlands
Haukland University Hospital
Bergen, Norway
Norwegian Radium Hospital
Oslo, Norway
University Hospital of the 'K. Marcinkowski' Medical University
Poznan, Poland
SPSK 2, Pomeranian Medical University
Szczecin, Poland
Wojskowy Instytut Medyczny - Centralny Szpital Kliniczny MON
Warszawa, Poland
Hosptial Nuestra Senora de Sonsoles
Avila, Spain
Hospital Duran i Reynals. Insitut Catala Oncologia
Barcelona, Spain
Hospital Moises Broggi
Barcelona, Spain
Hosptial Clinic de Barcelona
Barcelona, Spain
Hosptial Universitario Reina Sofia
Cordoba, Spain
Hospital 12 de Octubre, Madrid
Madrid, Spain
Hospital Ramon y Cajal
Madrid, Spain
Carlos Haya Hospital
Malaga, Spain
Hospital Universitario Central de Asturias
Oviedo, Spain
Hospital Son Llatzer
Palma de Mallorca, Spain
Hosptial Universitario Donostia
San Sebastian, Spain
Complejo Hospitalario
Santiago de Compostela, Spain
Hospital Univeritario Virgen Macarena
Sevilla, Spain
Hospital Virgen de la Salud
Toledo, Spain
The Valencian Institute of Oncology
Valencia, Spain
Karolinska University Hospital
Stockholm, Sweden
Kliniska provningar
Uppsala, Sweden
United Kingdom
City Hospital
Birmingham, United Kingdom
Royal Marsden NHS Foundation Trust
London, United Kingdom
Sarah Cannon Research UK
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Royal Marsden NHS Foundation Trust
Sutton, United Kingdom
Sponsors and Collaborators
Array BioPharma
Layout table for investigator information
Study Director: Array BioPharma 303-381-6604

Layout table for additonal information
Responsible Party: Array BioPharma Identifier: NCT01849874     History of Changes
Other Study ID Numbers: ARRAY-162-311
2013-000277-72 ( EudraCT Number )
First Posted: May 9, 2013    Key Record Dates
Last Update Posted: January 11, 2019
Last Verified: January 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Fallopian Tube Diseases
Adnexal Diseases
Genital Diseases, Female
Abdominal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases